Program
zanidatamab
Also written as “Zanidatamab” and “ZW25 (Zanidatamab)”.
Its studies are mostly in Breast Neoplasms · Biliary Tract Neoplasms · Stomach Neoplasms, led by 2 companies.
Drug pageZanidatamab: every studyAll 31 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jazz Pharmaceuticalsits history only | 105 open or running | phase 3since Nov 5, 2021 | Aug 23, 2016 | Dec 31, 2026phase 2 · NCT06695845 |
| BeOne Medicines | 10 open or running | phase 3since Nov 14, 2019 | Nov 14, 2019 | none ahead |
Also a collaborator on its studies: Jazz Pharmaceuticals Ireland and ALX Oncology.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseBeiGene (now BeOne) licensed it from Zymeworks, for Asia (except Japan), Australia and New Zealand.Announced Nov 27, 2018 · Source: Zymeworks and BeiGene (8-K exhibit), Nov 27, 2018
- LicenseJazz licensed it from Zymeworks, for everywhere outside the Asia-Pacific territories licensed to BeiGene.Announced Oct 19, 2022 · Source: Jazz and Zymeworks (8-K exhibit), Oct 19, 2022
History and studies of BeOne Medicines only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Nov 27, 2018BeiGene (now BeOne) licensed it from ZymeworksLicenseAsia (except Japan), Australia and New Zealand · announced · Zymeworks and BeiGene (8-K exhibit)
- Jun 9, 2019Named zanidatamabINNProposed as its International Nonproprietary Name in WHO's List 121
- Nov 14, 2019First study: phase 3 study in Advanced MalignanciesFirst studyNCT04164199 · 404 enrolled · United States, Australia, China and more
- Oct 19, 2022Jazz licensed it from ZymeworksLicenseEverywhere outside the Asia-Pacific territories licensed to BeiGene · announced · Jazz and Zymeworks (8-K exhibit)
TargetBeta
“An engineered immunoglobulin G1 (IgG1) bi-specific monoclonal antibody that targets two different non-overlapping epitopes of the human tumor-associated antigen (TAA) epidermal growth factor receptor 2 (HER2), ECD2 and ECD4, ”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
The one study BeOne Medicines leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04164199Advanced Malignancies · United States, Australia, China and more | 3 | Completed | May 23, 2026 | 404 |
How it is read
Names in the registry
- “Zanidatamab”, 7 entries
- “ZW25 (Zanidatamab)”, 4 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 5 studies
- Biliary Tract Neoplasms, 3 studies
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.